Keywords: bay, 43-9006, enters, ph, iii, kidney, cancer

BAY 43-9006 enters Ph III kidney cancer trial

Article | 03 November 2003

Print This

Bayer and Onyx Pharmaceuticals have initiated a pivotal Phase III trialto evaluate BAY 43-9006 as a potential treatment for advanced ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in